Rabbit Recombinant Monoclonal PD-L2 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human samples.
pH: 7.4
Constituents: 100% PBS
ICC/IF | IP | Flow Cyt | WB | IHC-P | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Tested | Tested |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Select an associated product type
Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production (By similarity).
CD273, B7DC, PDCD1L2, PDL2, PDCD1LG2, Programmed cell death 1 ligand 2, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2, Butyrophilin B7-DC, B7-DC
Rabbit Recombinant Monoclonal PD-L2 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human samples.
pH: 7.4
Constituents: 100% PBS
ab288308 is the carrier-free version of Anti-PD-L2 antibody [EPR25200-50] ab288298.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
PD-L2 also known as PDCD1LG2 or B7-DC is a member of the B7 protein family that plays a role in immune system regulation. This protein has a molecular mass of approximately 25 kDa. PD-L2 is expressed in antigen-presenting cells such as dendritic cells and macrophages. Expression is also located in some subsets of T cells and B cells. The PD-L2 can act as a second ligand for the PD-1 receptor which is important in immune checkpoints.
PD-L2 offers protection to tissues from autoimmunity by regulating T-cell activation and fostering tolerance. By engaging with its receptor PD-1 PD-L2 forms a complex that modulates the immune response to prevent overactivation. This interaction limits the immune system's potential damage to healthy tissues maintaining proper immune function in diverse environments.
PD-L2 participates in the immune checkpoint pathways where it works closely with PD-1 to mediate immune responses. PD-L2 forms an important part of the program death-1 (PD-1) pathway which plays a prominent role in downregulating T-cell activity. It relates to proteins such as PD-L1 which also interacts with PD-1 modulating immune tolerance and response to infections or tumors.
PD-L2 involvement has been significant in cancer immunology and autoimmune conditions. Its interaction with PD-1 relates to the suppression of immune responses in tumors contributing to cancer progression. PD-L2's function as an immune checkpoint ligand associates with autoimmune diseases like rheumatoid arthritis where immune regulation goes awry. Both PD-1 and PD-L2 represent potential targets for therapeutic interventions due to their roles in these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labelling PD-L2 with Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/1000 (0.546 ug/ml) followed by a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection) was used. Positive staining is found in the germinal centre of human tonsil. The section was incubated with Anti-PD-L2 antibody [EPR25200-50] ab288298 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
PD-L2 was immunoprecipitated from 0.35 mg HDLM-2 (human Hodgkin lymphoma) whole cell lysate with Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: HDLM-2 (human Hodgkin lymphoma) whole cell lysate 10 ug
Lane 2: Anti-PD-L2 antibody [EPR25200-50] ab288298 IP in HDLM-2 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-PD-L2 antibody [EPR25200-50] ab288298 in HDLM-2 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 92 seconds
All lanes: Immunoprecipitation - Anti-PD-L2 antibody [EPR25200-50] (Anti-PD-L2 antibody [EPR25200-50] ab288298)
Predicted band size: 31 kDa
Observed band size: 45-60 kDa
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Negative control: Jurkat (PMID: 27631416).
Exposure time: 125 seconds
All lanes: Western blot - Anti-PD-L2 antibody [EPR25200-50] (Anti-PD-L2 antibody [EPR25200-50] ab288298) at 1/1000 dilution
Lane 1: HDLM-2 (human Hodgkin lymphoma) whole cell lysate at 20 µg
Lane 2: Jurkat (human T cell leukemia T lymphocyte) whole cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 31 kDa
Observed band size: 45-60 kDa
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human breast cancer tissue labelling PD-L2 with Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/1000 (0.546 ug/ml) followed by a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection) was used. Positive staining on human breast cancer. The section was incubated with Anti-PD-L2 antibody [EPR25200-50] ab288298 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Panel A HDLM-2 Panel B Jurkat labelling PD-L2 with Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/1000 (0.546 ug/ml) followed by a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection) was used. Positive cell line HDLM-2 (Panel A) was positive and negative cell line Jurkat (Panel B) was negative.The section was incubated with Anti-PD-L2 antibody [EPR25200-50] ab288298 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins
This data was developed using Anti-PD-L2 antibody [EPR25200-50] ab288298, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human endometrial cancer tissue labelling PD-L2 with Anti-PD-L2 antibody [EPR25200-50] ab288298 at 1/1000 (0.546 ug/ml) followed by a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection) was used. Positive staining on human endometrial cancer (PMID:27446374). The section was incubated with Anti-PD-L2 antibody [EPR25200-50] ab288298 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™, Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com